StockData
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

TRINITY BIOTECH PLC

Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 30, 2026
$8.19+0.16 (+1.99%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

About Trinity Biotech

In Vitro & In Vivo Diagnostic Substances, SIC 2835

Trinity Biotech operates in the healthcare diagnostics industry, focusing on research, development, and manufacturing of medical diagnostic solutions. The company conducts its operations across three primary business segments: Clinical Laboratory, Laboratory Services, and Point of Care. Its offerings and developmental projects include continuous glucose monitoring testing devices and Premier instruments, alongside clinical testing capabilities. The organization serves a global customer base comprising healthcare clients and laboratory purchasers located across the Americas, Europe, Asia, and Africa.

The company's geographic footprint and operational scale extend internationally, with named operating entities, facilities, and regional exposure in Ireland, the United States, Sweden, and Luxembourg. Its corporate structure includes specialized units such as Trinity Biotech Manufacturing, Trinity Research, Clark Laboratories, and Fiomi Diagnostics. While the provided text references primary activities and regional disclosures spanning Europe and North America, it does not explicitly designate a formal corporate headquarters location.

Summary of the business section of Trinity Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
TRINITY BIOTECH PLC
Headquarters
Wicklow, Ireland
Address
Ida Business Park, Bray
Phone
01135312955111
Employees
287, Dec 31, 2025
Industry
In Vitro & In Vivo Diagnostic Substances
Incorporated in
L2
Fiscal year ends
December 31
Auditor
GRANT THORNTON, Dublin, Ireland

Stock & identifiers

Ticker
TRIB
Exchange
Nasdaq
Shares outstanding
374M, Dec 31, 2025
Filer category
Non-accelerated filer
Stock splits
1-for-30 reverse, Jul 24, 2026; 1-for-5 reverse, Feb 23, 2024; 1-for-4 reverse, Jun 2, 2005
SEC CIK
888721
CUSIP
896438504
ISIN
US8964385046
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul MurphyInterim CFO–
Ronan O'CaoimhDirector486,208
John GillardDirector10,000
John Paul TivnanDirector–
Andrew OmidvarDirector–

Employees

Headcount reported in annual reports

“The following table details certain data on the average number of employees of Trinity Biotech and its consolidated subsidiaries, including full-time, part-time, and temporary personnel who work under the direction and supervision of the Company: … Total workforce 287 401 380”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 30, 2025Late filingNotification of late filing
May 1, 2023Late filingNotification of late filing
May 1, 2019Late filingNotification of late filing
Jul 1, 2003Late filingNotification of late filing